Evidence map›Paper›PMID 34688639›Full record

ArticleEnvironmental research2022

The global transmission of new coronavirus variants.

Yingjie Zhao, Jianping Huang, Li Zhang, Siyu Chen, Jinfeng Gao, Hui Jiao

Abstract read
In one paragraph

Article in Environmental research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yingjie ZhaoCollaborative Innovation Centre for West Ecological Safety (CIWES), Lanzhou University, Lanzhou, 730000, China.
Jianping HuangCollaborative Innovation Centre for West Ecological Safety (CIWES), Lanzhou University, Lanzhou, 730000, China; College of Atmospheric Sciences, Lanzhou University, Lanzhou, China. Electronic address: hjp@lzu.edu.cn.
Li ZhangCollaborative Innovation Centre for West Ecological Safety (CIWES), Lanzhou University, Lanzhou, 730000, China; College of Atmospheric Sciences, Lanzhou University, Lanzhou, China.
Siyu ChenCollaborative Innovation Centre for West Ecological Safety (CIWES), Lanzhou University, Lanzhou, 730000, China; College of Atmospheric Sciences, Lanzhou University, Lanzhou, China.
Jinfeng GaoCollaborative Innovation Centre for West Ecological Safety (CIWES), Lanzhou University, Lanzhou, 730000, China.
Hui JiaoCollaborative Innovation Centre for West Ecological Safety (CIWES), Lanzhou University, Lanzhou, 730000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus Disease 2019 (COVID-19) has caused tremendous losses to the world. This study addresses the impact and diffusion of the five major new coronavirus variants namely Alpha, Beta, Gamma, Eta, and Delta lineage. The results of this study indicate that Africa and Europe will be affected by new coronavirus variants the most compared with other continents. The comparative analysis indicates that vaccination can contain the spread of the virus in most of the continent, and non-pharmaceutical interventions (NPIs), such as restriction on gatherings and close public transport, will effectively curb the pandemic, especially in densely populated continents. According to our Global Prediction System of COVID-19 Pandemic, the diffusion of delta lineage in the US shows seasonal oscillation characteristics, and the first wave will occur in October 2021, with the record of 323,360, and followed by a small resurgence in April 2022, with the record of 184,196, while the second wave will reach to 232,622 cases in October 2022. Our study will raise the awareness of new coronavirus variants among the public, and will help the governments make appropriate directives to cope with the new coronavirus variants.

Indexed as

COVID-19PandemicsAfricaEuropeHumansSARS-CoV-2COVID-19New coronavirus variantsNon-pharmaceutical interventionsVaccines

Identifiers

PMID34688639
PMCPMC8530777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.